<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03328507</url>
  </required_header>
  <id_info>
    <org_study_id>BLI4900-201</org_study_id>
    <nct_id>NCT03328507</nct_id>
  </id_info>
  <brief_title>A Pilot Evaluation of BLI4900 Bowel Preparation in Adult Subjects</brief_title>
  <official_title>A Pilot Evaluation of BLI4900 Bowel Preparation in Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braintree Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Braintree Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of BLI4900 as a bowel
      preparation prior to colonoscopy in adult patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2017</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% of subjects with successful bowel preparation</measure>
    <time_frame>Day of colonoscopy</time_frame>
    <description>% of subjects with successful bowel preparation rated by blinded colonoscopist on a 4 point scale (1=poor to 4 = excellent)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Colonoscopy</condition>
  <arm_group>
    <arm_group_label>BLI4900</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BLI4900 Bowel Preparation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PEG Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polyethylene glycol-based bowel preparation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLI4900</intervention_name>
    <description>BLI4900 Bowel Preparation</description>
    <arm_group_label>BLI4900</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG Control</intervention_name>
    <description>Polyethylene glycol-based bowel preparation</description>
    <arm_group_label>PEG Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients who are undergoing colonoscopy for a routinely accepted
             indication.

          -  18 to 85 years of age (inclusive).

          -  If female, and of child-bearing potential, is using an acceptable form of birth
             control (hormonal birth control, IUD, double-barrier method, depot contraceptive,
             abstinent, or vasectomized spouse).

          -  Negative urine pregnancy test at screening, if applicable.

          -  In the Investigator's judgment, subject is mentally competent to provide informed
             consent to participate in the study.

        Exclusion Criteria:

          -  Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal
             obstruction, gastric retention, bowel perforation, toxic colitis or megacolon.

          -  Subjects with ongoing severe, acute inflammatory bowel disease.

          -  Subjects who had previous significant gastrointestinal surgeries.

          -  Subjects with uncontrolled pre-existing electrolyte abnormalities, or those with
             clinically significant electrolyte abnormalities based on Visit 1 laboratory results.

          -  Subjects with uncontrolled hypertension (systolic blood pressure &gt; 170 mmHg and
             diastolic blood pressure &gt; 100 mmHg).

          -  Subjects with severe renal insufficiency (GFR &lt; 30 mL/min/1.73m2).

          -  Subjects with known severe hepatic insufficiency (Child Pugh C).

          -  Subjects with cardiac insufficiency (NYHA Functional Classifications 3 or 4).

          -  Subjects undergoing insulin therapy for any indication.

          -  Subjects with impaired consciousness that predisposes them to pulmonary aspiration.

          -  Subjects undergoing colonoscopy for foreign body removal and/or decompression.

          -  Subjects who are pregnant or lactating, or intending to become pregnant during the
             study.

          -  Subjects of childbearing potential who refuse a pregnancy test.

          -  Subjects allergic to any preparation components.

          -  Subjects who, in the opinion of the Investigator, should not be included in the study
             for any reason, including inability to follow study procedures.

          -  Subjects who have participated in an investigational surgical, drug, or device study
             within the past 30 days.

          -  Subjects who withdraw consent before completion of Visit 1 procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John McGowan, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Braintree Laboratories, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John McGowan, MPH</last_name>
    <phone>781-843-2202</phone>
    <email>jmcgowan@braintreelabs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Braintree Research Site 1</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>October 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2017</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

